Perspectives of Alzheimer's disease treatments

Handbook of Clinical Neurology

Volumn 89, Issue , 2008, Pages 273-290

  Davis, John B ^a   Bountra, C ^a   Richardson, J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; BEHAVIOR; COGNITIVE DEFECT; DRUG EFFECT; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; REVIEW;

ALZHEIMER DISEASE; AMYLOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; HUMANS; IMMUNOMODULATION;

EID: 66049154498     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)01226-2     Document Type: Review

References (139)

1. Allman D., Punt J.A., Izon D.J., et al. An invitation to T and more: Notch signaling in lymphopoiesis. Cell 109 (2002) S1-S11
2. Andreasen N., and Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 107 (2005) 165-173
3. Arendash G.W., Sengstock G.J., Sanberg P.R., et al. Improved learning and memory in aged rats with chronic administration of the nicotinic reporter agonist GTS-21. Brain Res 674 (1995) 252-259
4. Areosa S.A., and Sherriff F. Memantine for Dementia (Cochrane Review) (2003), The Cochrane Library, Oxford Issue 1, 2003. Update Software
5. Bales K., Verina T., Dodel R.C., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17 (1997) 263 46
6. Bard F., Cannon C., Barbour R., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6 (2000) 916-919
7. Bayer A.J., Bullock R., Jones R.W., et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64 (2005) 94-101
8. Bliss T.V., and Collingridge G.L. A synaptic model of memory: Long term potentiation in the hippocampus. Nature 361 (1993) 31-39
9. Bodendorf U., Danner S., Fischer F., et al. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem 80 (2002) 799-806
10. Bourin M., Ripoll N., and Dailly E. Nicotinic receptors and Alzheimer's disease. Curr Med Res Opin 19 (2003) 169-177
11. Brioni J.D., O'Neill A.B., Kim D.J., et al. Anxiolytic-like effects on the novel cholinergic channel activator ABT-418. J Pharmacol Exp Ther 271 (1994) 353-361
12. Buccafusco J.J., Jackso W.J., Terry Jr. A.V., et al. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: A novel cholinergic channel activator for memory enhancement. Psychopharmacology (Berl) 120 (1995) 256-266
13. Cai H., Wang Y., McCarthy D., et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4 (2001) 233-234
14. Camacho I.E., Serneels L., Spittaels K., et al. Peroxisome Proliferator-Activated Receptor induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24 (2004) 10908-10917
15. Cherny R.A., Atwood C.S., Xilinas M.E., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
16. Cleary J.P., Walsh D.M., Hofmeister J.J., et al. Natural oligomers of the amyloid- protein specifically disrupt cognitive function. Nat Neurosci 8 (2004) 79-84
17. Cook D.G., Leverenz J.B., McMillan P.J., et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with apoliprotein E-epsilon 4 allele. Am J Path 162 (2003) 313-319
18. Court J., Martin-Cruz, Piggott M., et al. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49 (2001) 175-184
19. Cowart M., Faghih R., Curtis M.P., et al. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. J Med Chem 48 (2005) 38-55
20. Craft S., Peskind E., Schwartz M.W., et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50 (1998) 164-168
21. Dartigues J.F., and Letenneur L. Genetic epidemiology of Alzheimer's disease. Curr Opin Neurol 13 (2000) 385-389
22. DeMattos R.B., Bales K.R., Cummins D.J., et al. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 (2001) 8850-8855
23. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 38 (2003) 9-12
24. Dodart J., Bales K.R., Gannon K.S., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 5 (2002) 452-457
25. Dominguez D., Tournoy J., Hartmann D., et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280 (2005) 30797-30806
26. Dovey H.F., John V., Anderson J.P., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76 (2001) 173-181
27. Eriksen J., Sage S.A., Smith T.E., et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Aβ42 in vivo. J Clin Invest 112 (2003) 440-449
28. Farris W., Mansourian S., Leissring M.A., et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein. Am J Pathol 164 (2004) 1425-1434
29. Fassbender K., Simons M., Bergmann C., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98 (2001) 5856-5861
30. Flynn D., and Mash D. Characterization of L-[3H] nicotine binding in human cerebral cortex: Comparison between Alzheimer's disease and the normal. J Neurochem 47 (1986) 1948-1954
31. Foley A.G., Murphy K.J., Hirst W.D., et al. The 5-HT6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 29 (2004) 93-100
32. Fox G.B., Pan J.B., Esbenshade T., et al. Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 131 (2002) 151-161
33. Fox G.B., Pan J.B., Faghih R., et al. Identification of novel H3 receptor (H3R) antagonists with cognition enhancing properties in rats. Inflamm Res 52 (2003) S31-S32
34. Fox G.B., Pan J.B., Lewis A.M., et al. Cognition enhancing effects of novel H(3) receptor (H(3)R) antagonists in several animal models. Inflamm Res 53 (2004) S49-S50
35. Fox N.C., Black R.S., Gilman S., et al., for the AN1792(QS-21)-201 Study Team. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005) 1563-1572
36. Fryer J.D., Simmons K., Parsadanian M., et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 25 (2005) 2803-2810
37. Games D., Adams D., Alessandrini R., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
38. Gemma C., Stellwagen H., Fister M., et al. Rosiglitazone improves contextual fear conditioning in aged rats. Neuroreport 15 (2004) 2255-2259
39. Gerlai R. Behavioural tests of hippocampal function: simple paradigms complex problems. Behav Brain Res 125 (2001) 269-277
40. Gilman S., Koller M., Black R.S., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
41. Gitter B.D., Czilli D.L., Li W., et al. Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor. Neurobiol Aging 25 (2004) 571
42. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120 (1984) 885-890
43. Glennon R.A. Higher-end serotonin receptors: 5-HT5, 5-HT6 and 5-HT7. J Med Chem 46 (2003) 2795-2812
44. Golde T.E., and Eckman C.B. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discov Today 20 (2001) 1049-1055
45. Gong Y., Chang L., Viola K.L., et al. Alzheimer's disease-affected brain: Presence of oligomeric Ab ligands (ADDLs) suggests a molecular basis for memory loss. Proc Natl Acad Sci USA 100 (2003) 0417-10422
46. Granger R., Staubli U., Davis M., et al. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in learning dependant task. Synapse 15 (1993) 326-329
47. Greenamyre J.Y., and Porter R.H. Anatomy and physiology of glutamate in CNS. Neurology 44 (1994) S9-S13
48. Greenamyre J.Y., and Young A.B. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10 (1989) 593-602
49. Hancock A.A., and Fox G.B. Perspectives on cognition domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 13 (2004) 1237-1248
50. Hartman R.E., Izumi Y., Bales K.R., et al. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci 25 (2005) 6213-6220
51. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
52. Ho L., Qin W., Pompl P.N., Xiang Z., et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18 (2004) 902-904
53. Hock C., Konietzko U., Streffer J.R., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
54. Hock C., Maddalena A., Raschig A., et al. Treatment with the selective muscarinic M1 agonist talsaclidine decreases cerebospinal fluid levels of Abeta 42 in patients with Alzheimer's disease. Amyloid 10 (2003) 1-6
55. Holladay M.W., Dart M.J., and Linch J.K. Neuronal nicotinic receptors as targets for drug discovery. J Med Chem 40 (1997) 4169-4193
56. Holtzman D.M., Bales K.R., Tenkova T., et al. Apolipoprotein E isoform-dependant amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97 (2000) 2892-2897
57. Hussain I., Powell D., Howlett D.R., et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14 (1999) 419-427
58. Ikeuchi T., and Sisodia S.S. The Notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent "gamma-secretase" cleavage. J Biol Chem 278 (2003) 7751-7754
59. Janus C., Pearson J., McLaurin J., et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
60. Jarvik G.P., Wijsman E.M., Kukull W.A., et al. Interactions of apolipoprotein E genotype, total cholesterol level, age and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45 (1995) 1092-1096
61. Jensen J., Pedersen E.E., Galante P., et al. Control of endodermal endocrine development by Hes-1. Nat Genet 24 (2000) 36-44
62. Jick H. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
63. Jones G.M.M., Sahakian B.J., Levy R., et al. Effects of acute subcutaneous nicotine on attention, information processing and short term memory in Alzheimer's disease. Psychopharmacology (Berl) 108 (1992) 485-494
64. Josien H. Recent advances in the development of γ-secretase inhibitors. Curr Opin Drug Discovery Dev 5 (2002) 513-525
65. Kim D.Y., Ingano L.A., Carey B.W., et al. Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta 2-subunit regulates cell adhesion and migration. J Biol Chem 17 (2005) 23251-23261
66. Kitazume S., Tachida Y., Oka R., et al. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage and secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci USA 98 (2001) 13554-13559
67. Kojro E. Low cholesterol stimulates non-amyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 98 (2001) 5815-5820
68. Komater V.A., Browman K.E., Curzon P., et al. H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl) 167 (2003) 363-372
69. Kuusisto J., Koivisto K., Mykkanen L., et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apoliprotein E4 phenotype: Cross sectional population based study. Br Med J 315 (1997) 1045-1049
70. Lammich S., Okochi M., Takeda M., et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Aβ-like peptide. J Biol Chem 277 (2002) 44754-44759
71. Lane H., Lin C., Huang C., et al. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophrenia Res 67 (2004) 63-70
72. Lauterborn J.C., Lynch G., Vanderklish P., et al. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 20 (2000) 8-21
73. Lebrun C., Pilliere E., and Lestage P. Effects of S18986-1, a novel cognition enhancer, on memory performances in an object recognition task. Eur J Pharmacol 401 (2000) 205-212
74. Leurs R., Blandina P., Tedford C., et al. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 19 (1998) 177-183
75. Li Q., and Südhof T.C. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J Biol Chem 279 (2003) 10542-10550
76. Lichtenthaler S.F., Dominguez D.I., Westmeyer G.G., et al. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J Biol Chem 278 (2003) 48713-48719
77. Ligneau X., Lin J., Vanni-Mercier G., et al. Neurochemical and behavioural effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287 (1998) 658-666
78. Lippiello P.M., Bencherif M., Gray J.A., et al. RJR-2403: A nicotinic agonist with CNS selectivity II: In vivo characterization. J Pharmacol Exp Ther 279 (1996) 1422-1429
79. Lloyd G.K., Menzaghi F., Bontempi B., et al. The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci 62 (1998) 1601-1606
80. Lue L., Kuo Y., Roher A.E., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155 (1999) 853-862
81. Luo Y., Bolon B., Kahn S., et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4 (2001) 231-232
82. Lynch G., Granger R., Ambros-Ingerson J., et al. Evidence that a positive modulator of AMPA-type receptors improves delayed recall in aged humans. Exp Neurol 145 (1997) 89-92
83. McClure D.E. The potential therapeutic usefulness of subtype selective neuronal nicotinic acetylcholine receptor agonists for the motor, cognitive, and disease progression components of Parkinson's disease. Presented at IBC 2nd International Symposium on Nicotinic Acetylcholine Receptors: Advances in Molecular Pharmacology and Drug Development, Annapolis, MD (1999)
84. Meneses A. Review of 5-HT system and cognition. Neurosci Biobehav Rev 23 (1999) 1111-1125
85. Morgan D., Diamond D.M., Gottschall P.E., et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
86. Ness D.K., Boggs L.N., Hepburn D.L., et al. Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol Aging 25 (2004) 238-239
87. Newhouse P.A., Sunderland T., Tariot P.N., et al. Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology (Berl) 95 (1988) 171-175
88. Newhouse P.A., Potter A., and Corwin J. Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease. Drug Dev Res 38 (1996) 278-289
89. Ni C.Y., Murphy M.P., Golde T.E., et al. Gamma-secretase cleavage and nuclear localization of erbB-4 receptor tyrosine kinase. Science 294 (2001) 2179-2181
90. Nicoll J., Wilkinson D., Holmes C., et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med 9 (2003) 448-452
91. Ohno M., Sametsky E.A., Younkin L.H., et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41 (2004) 27-33
92. Orsetti M., Ferretti C., Gamalero R., et al. Histamine H3-receptor blockade in the rat nucleus basalis magnocellularis improves place recognition memory. Psychopharmacology (Berl) 159 (2002) 133-137
93. Pangalos M.N., Jacobsen S.J., and Reinhart P.H. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of β-amyloid peptide. Biochem Soc Trans 33 (2005) 553-558
94. Passani M.B., Bacciottini L., Mannaioni P.F., et al. Central histaminergic system and cognition. Neurosci Biobehav Rev 24 (2000) 107-113
95. Perry E.K., Morris C.M., Court J.A., et al. Alteration in nicotinic binding sites in Parkinson's disease, Lewy body dementia, and Alzheimer's disease: Possible index of early neuropathology. Neuroscience 64 (1995) 385-395
96. Potter A., Corwin J., Lang K., et al. Acute effects of the selective cholinergic channel activator (Nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology 142 (1999) 334-342
97. Prast H., Argyriou A., and Philippu A. Histaminergic neurons facilitate social memory in rats. Brain Res 734 (1996) 316-318
98. Puglielli L., Konopka G., Pack-Chung E., et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyolid beta-peptide. Nat Cell Biol 3 (2001) 905-912
99. Razay G., and Wilcock G.K. Hyperinsulinaemia and Alzheimer's disease. Age Ageing 23 (1994) 396-399
100. Reavill C., and Rogers D.C. The therapeutic potential of 5-HT6 receptor antagonists. Curr Opin Invest Drugs 2 (2001) 104-109
101. Refolo L.M., Malester B., LaFrancois J., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7 (2000) 321-331 Erratum in: Neurobiol Dis 7: 690
102. Refolo L.M., Pappolla M.A., LaFrancois J., et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8 (2001) 890-899
103. Regan C.M., Foley A.G., Murphy K.J., et al. The 5-HT6 receptor antagonists SB-271046 and SB-399885 increase basal and learning induced NCAM-polysialylation in the rat dentate gyrus. Society for Neuroscience 33rd Annual Meeting, New Orleans, USA (2003) (Abstract no. 835.21)
104. Regland B., Lehmann W., Abedini I., et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 12 (2001) 408-414
105. Reisberg B., Doody R., Stoffler A., et al. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1341
106. Ritchie C.W., Bush A.I., Mackinnon A., et al. Metal- protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60 (2003) 1685-1691
107. Robbins T., and Everitt B. Arousal systems and attention. In: Gazzangia M. (Ed). The Cognitive Neurosciences (1995), MIT Press, Cambridge, MA 703-720
108. Roberds S.L., Anderson J., Basi G., et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: Implications for Alzheimer's disease therapeutics. Hum Mol Genet 10 (2001) 1317-1324
109. Sahakian B.J., and Coull J.T. Nicotine and THA: Evidence for improved attention in patients with dementia of the Alzheimer type. Drug Res 31 (1994) 80-88
110. Sastre M., Dewachter I., Landreth G.E., et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferators-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23 (2003) 9796-9804
111. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
112. Shepherd J., Blauw G.J., Murphy M.B., et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360 (2002) 1623-1630
113. Shibata M., Yamada S., Kumar S.R., et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106 (2000) 1489-1499
114. Siemers E., Skinner M., Dean R.A., et al. Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers. Clin Neuropharmacol 28 (2005) 126-132
115. Simons M., Keller P., De Strooper B., et al. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95 (1998) 6460-6464
116. Sing C.F., and Davingnon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37 (1985) 268-285
117. Sinha S., Anderson J.P., Barbour R., et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402 (1999) 537-540
118. Spalding T.A., Trotter C., Skjaerbaek N., et al. Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol Pharmacol 61 (2002) 1297-1302
119. Sparks D.L., Scheff S.W., Hunsaker III J.C., et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126 (1994) 88-94
120. Staubli U., Rogers G., and Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 91 (1994) 777-781
121. Sucher N.J., Awobuluyi M., Choi Y.B., et al. NMDA receptors: from genes to channels. Trends Pharmacol Sci 17 (1996) 348-355
122. Tariot P.N., Farlow M.R., Grossberg G.T., et al., Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291 (2004) 317-324
123. Terry Jr. A.V., Buccafusco J.J., Jackson W.J., et al. Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17071. Psychopharmacology 135 (1998) 407-415
124. Vassar R., Bennett B.D., Babu-Khan S., et al. Beta- secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
125. Warpman U., and Nordberg A. Epibatidine and ABT-418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 6 (1995) 2419-2423
126. Watson G.S., Cholerton B.A., Reger M.A., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13 (2005) 950-958
127. Weggen S., Eriksen J.L., Das P., et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
128. Whitehouse P., Martino A., Antuono P.G., et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 371 (1986) 146-151
129. Wilcock D.M., DiCarlo G., Henderson D., et al. Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23 (2003) 3745-3751
130. Wilcock D.M., Munireddy S.K., Rosenthal A., et al. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiology of Disease 15 (2004) 1-20
131. Wilcock D.M., Rojiani A., Rosenthal A., et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhaemorrhage. J Neuroinflammation 1 (2004) 24
132. Wilens T., Biederman J., Spencer T., et al. A controlled trial of ABT-418 in attention deficit hyperactivity disorder in adults. Am J Psychiatry 156 (1998) 1931-1937
133. Wilson A.L., Langley L.K., Monley J., et al. Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety. Pharmacol Biochem Behav 51 (1995) 509-514
134. Wolozin B. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 (2000) 1439-1443
135. Wong G.T., Manfra D., Poulet F.M., et al. Chronic treatment with the γ-secretase inhibitor LY-411575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279 (2004) 12876-12882
136. Wong H.K., Sakurai T., Oyama F., et al. Beta subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem 280 (2005) 23009-23017
137. Yamada K.A. Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease. Exp Opin Invest Drugs 9 (2000) 765-777
138. Yan R., Bienkowski M.J., Shuck M.E., et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402 (1999) 533 337
139. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J Neurochem 89 (2004) 807-811